Nutex Health and Elevance Health are recommended as undervalued healthcare stocks despite strong year-to-date performance. Nutex, a small-cap hospital operator, trades at less than 9x trailing earnings with exceptional EPS growth of 2,785% year-over-year. Elevance, a major health insurer, trades at a forward P/E of 14.52 below its five-year average, with consistent dividend increases and strong earnings guidance for 2026-2027.

Five stocks have demonstrated significant price strength and improved earnings estimates following a mixed September market performance. Vince Holding, Vera Bradley, American Outdoor Brands, Nutex Health, and Forum Energy Technologies were identified using screening criteria including positive 4-week price momentum, Zacks Rank #1 ratings, and trading near 52-week highs. All five companies show expected earnings growth exceeding 60% for their current fiscal years.

Four stocks—Nutex Health (NUTX), RCM Technologies (RCMT), Interface (TILE), and Quad/Graphics (QUAD)—were selected based on strong net profit margins, solid EPS growth outlooks, and positive analyst ratings. All four stocks carry Zacks Rank 1 or 2 ratings and VGM Scores of A or B, with recent upward earnings estimate revisions over the past 60 days.

Four companies—Nutex Health (NUTX), RCM Technologies (RCMT), Remitly Global (RELY), and Belden (BDC)—demonstrate strong net profit margins and positive earnings revisions for fiscal 2026. All four stocks carry Zacks Rank ratings of 1 or 2 with VGM Scores of A or B, indicating solid upside potential. Each company has also beaten consensus earnings estimates in their most recent quarters.

Block & Leviton is investigating multiple companies for securities fraud. Aldeyra Therapeutics (ALDX) shares fell 65% after the FDA rejected its reproxalap drug application for dry eye disease, citing failure to demonstrate efficacy. The firm is also investigating Eos Energy Enterprises (EOSE) and Nutex Health (NUTX) for potential securities violations. Investors who have lost money are encouraged to contact the law firm.

Law firm Lowey Dannenberg is investigating Nutex Health, Inc. (NUTX) for potential federal securities law violations after the company's stock fell over 24% on March 6, 2026. Nutex disclosed a $55 million cumulative true-up related to 18,950 arbitration claims deemed ineligible under the Independent Dispute Resolution process. The firm is seeking investors with losses exceeding $50,000.

The Schall Law Firm is investigating potential securities law violations by Nutex Health Inc. following a Blue Orca Capital report alleging improper billing practices, which caused the company's stock to drop 10.1%.

Law firm investigating potential claims against Nutex Health Inc. for allegedly making false and misleading statements about business operations, financial reporting, and engagement with HaloMD during August 2024-2025.

Law Offices of Frank R. Cruz is alerting Nutex Health shareholders about an upcoming October 21, 2025 deadline to participate in a securities fraud class action lawsuit, alleging the company made misleading statements about its business operations and financial reporting.

The Schall Law Firm is pursuing a class action lawsuit against Nutex Health Inc. for alleged securities fraud, claiming the company made false and misleading statements between August 2024 and August 2025.

A class action lawsuit has been filed against Nutex Health Inc. alleging fraudulent financial practices, misleading statements about revenues, internal control weaknesses, and improper financial reporting during August 2024-2025.

Nutex Health is facing a class-action lawsuit alleging fraudulent billing practices with third-party firm HaloMD, artificially inflating revenues through questionable insurance arbitration claims and misrepresenting financial statements.